Topas Therapeutics has almost doubled its series B round to $48m thanks to an extension backed by all of its shareholders.

Topas Therapeutics, a Germany-based developer of treatments for autoimmune diseases based on research at University of Hamburg, has extended its series B round by €18m ($22m) thanks to its existing investor base.
These shareholders are European Molecular Biology Laboratory’s EMBL Ventures, commercialisation firm Epidarex Capital, drug discovery company Evotec, pharmaceutical firm Boehringer Ingelheim’s Venture Fund, Gimv Vesalius BioCapital III and BioMedPartners.
Topas previously obtained an initial $26m in series B funding in October 2020 co-led by Vesalius BioCaptial…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in